Subject(s)
Adenoma/diagnosis , Colonic Neoplasms/diagnosis , Colonoscopy/methods , Humans , Male , Middle AgedSubject(s)
Carcinoma, Squamous Cell/pathology , Colitis, Ulcerative/diagnosis , Colonoscopy/methods , Image Enhancement/methods , Rectal Neoplasms/pathology , Biopsy, Needle , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/diagnosis , Colitis, Ulcerative/complications , Humans , Image Enhancement/instrumentation , Immunohistochemistry , Indigo Carmine , Intestinal Mucosa/pathology , Male , Middle Aged , Rectal Neoplasms/complications , Rectal Neoplasms/diagnosisABSTRACT
Using sections of formalin-fixed, paraffin-embedded tissues from 64 colorectal cancer patients, the expression of c-erbB-2 oncoprotein was studied immunohistochemically. Twenty-seven percent of the cases with liver metastasis showed positive staining. On the other hand, only 3% of cases without liver metastasis were positive. Expression rates of c-erbB-2 protein in liver metastasis cases showed no significant difference between primary operation (26%) and recurrence (27%). Of all c-erbB-2 positive patients, 90% (9/10) had liver metastasis. Secondly, vessel invasions of 45 rectal cancer patients were studied using Victoria Blue (VB) elastic staining and endothelial staining by factor VIII-related antigen and Ulex europaeus agglutinin I (UEA-I) lectin. VB-HE double stain was efficacious to detect vascular invasion, but endothelial staining was not. There were statistically more vascular invasions in 30 patients with liver or lymph node metastases than in those without metastasis. And in cases with metastasis, many vascular invasions into the extra-muscular layer were seen. Both vascular invasions and c-erbB-2 protein were valuable indicators of possible liver metastasis.
Subject(s)
Colonic Neoplasms/blood supply , Proto-Oncogene Proteins/metabolism , Biomarkers, Tumor/metabolism , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Humans , Liver Neoplasms/diagnosis , Liver Neoplasms/secondary , Lymphatic Metastasis , Neoplasm Invasiveness , Prognosis , Receptor, ErbB-2ABSTRACT
Continuous hepatic arterial infusion chemotherapy using implantable reservoir was performed for liver metastases from colorectal cancer, and the therapeutic effects, side effects, and complications were evaluated. 9 patients with unresectable liver metastases were as follows, 1. Group A; 3 patients, MMC 2 mg.one shot + 5-FU 250 mg/day.continuous infusion x 14 days, and then 5-FU tablets 150 mg/day.p.o. x 14 days, 2. Group B; 4 patients, MMC 2 mg.one shot + 5-FU 500 mg/day.continuous infusion x 7 days, and then 5-FU tablets 150 mg/day.p.o. x 14 days, 3. Group C; 2 patients, 5-FU 500 mg/day.continuous infusion x 14 days, and then free from agents for 14 days. In 2 of 3 group A patients, the catheters became dislocated and one died of perforation of duodenum. In group A and group B, no severe side effects were noted. But both of group C patients showed nausea, vomiting and diarrhea. In 8 of 9 patients (89%), serum CEA level fell below the preoperative level. In 4 of 7 patients who underwent CT scan, the size of the tumor regressed. Total infused dose of 5-FU was 8.17 +/- 7.56 g in group A, 16.9 +/- 2.88 g in group B, and 21.0 +/- 9.90 g in group C on average. In 2 patients of group B, therapy was repeated seven times.